Venous thromboembolism in malignant gliomas

Summary.  Malignant gliomas are associated with a very high risk of venous thromboembolism (VTE). While many clinical risk factors have previously been described in brain tumor patients, the risk of VTE associated with newer anti‐angiogenic therapies such as bevacizumab in these patients remains unclear. When VTE occurs in this patient population, concern regarding the potential for intracranial hemorrhage complicates management decisions regarding anticoagulation, and these patients have a worse prognosis than their VTE‐free counterparts. Risk stratification models identifying patients at high risk of developing VTE along with predictive plasma biomarkers may guide the selection of eligible patients for primary prevention with pharmacologic thromboprophylaxis. Recent studies exploring disordered coagulation, such as increased expression of tissue factor (TF), and tumorigenic molecular signaling may help to explain the increased risk of VTE in patients with malignant gliomas.

[1]  N. Mackman,et al.  Tumors, ticks and tissue factor , 2009, Journal of thrombosis and haemostasis : JTH.

[2]  M. Sogayar,et al.  Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model , 2009, Journal of thrombosis and haemostasis : JTH.

[3]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  O. Wagner,et al.  D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Erwin G. Van Meir,et al.  Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. , 2009, Cancer research.

[6]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  T. Meyer,et al.  Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice , 2009, Journal of thrombosis and haemostasis : JTH.

[8]  A. Guha,et al.  Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. , 2008, Cancer research.

[9]  Shenhong Wu,et al.  Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. , 2008, JAMA.

[10]  A. Falanga,et al.  Hemostatic complications of angiogenesis inhibitors in cancer patients , 2008, American journal of hematology.

[11]  P. Kelly,et al.  High-grade glioma before and after treatment with radiation and Avastin: initial observations. , 2008, Neuro-oncology.

[12]  J. Colon,et al.  Tissue factor‐bearing microparticles derived from tumor cells: impact on coagulation activation , 2008, Journal of thrombosis and haemostasis : JTH.

[13]  B. Furie,et al.  Mechanisms of thrombus formation. , 2008, The New England journal of medicine.

[14]  Clifford W Colwell,et al.  Prevention of Venous Thromboembolism* American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition) , 2008 .

[15]  T. Cloughesy,et al.  Safety of anticoagulation use and bevacizumab in patients with glioma. , 2008, Neuro-oncology.

[16]  Gary H Lyman,et al.  Development and validation of a predictive model for chemotherapy-associated thrombosis. , 2008, Blood.

[17]  A. Guha,et al.  Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells , 2008, Nature Cell Biology.

[18]  A. Amin,et al.  Prevention of venous thromboembolism in the cancer surgery patient. , 2008, Cleveland Clinic journal of medicine.

[19]  U. Ozbek,et al.  Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients , 2008, Medical oncology.

[20]  D. Brat,et al.  RESEARCH ARTICLE: Intravascular Thrombosis in Central Nervous System Malignancies: A Potential Role in Astrocytoma Progression to Glioblastoma , 2007, Brain pathology.

[21]  J. Nieva,et al.  Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. , 2008, Thrombosis research.

[22]  M. Gilbert,et al.  Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial , 2008, Cancer Chemotherapy and Pharmacology.

[23]  P. Kyrle,et al.  Chemotherapy‐induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity , 2007, Journal of thrombosis and haemostasis : JTH.

[24]  Gary H Lyman,et al.  American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Varki.  Trousseau's syndrome: multiple definitions and multiple mechanisms. , 2007, Blood.

[26]  A. Khorana,et al.  A meta‐analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment , 2007, Cancer.

[27]  M. Tesselaar,et al.  Risk of venous thromboembolism in lung cancer , 2007, Current opinion in pulmonary medicine.

[28]  Zhiwei Hu,et al.  Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. , 2007, Blood.

[29]  M. Malkin,et al.  PRODIGE: A phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma , 2007 .

[30]  Ralph H. Hruban,et al.  Tissue Factor Expression, Angiogenesis, and Thrombosis in Pancreatic Cancer , 2007, Clinical Cancer Research.

[31]  S. Fan,et al.  High Serum Vascular Endothelial Growth Factor Levels Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular Carcinoma: Importance of Tumor Biomarker in Ablative Therapies , 2007, Annals of Surgical Oncology.

[32]  H. Chew,et al.  Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. , 2007, Journal of neurosurgery.

[33]  C. Marosi,et al.  Venous thromboembolism and survival in patients with high-grade glioma. , 2007, Neuro-oncology.

[34]  C. Daskalakis,et al.  A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants , 2007, Journal of Thrombosis and Thrombolysis.

[35]  Darell D. Bigner,et al.  Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.

[36]  J. Segal,et al.  Venous thromboembolism occurs infrequently in meningioma patients receiving combined modality prophylaxis , 2007, Cancer.

[37]  S. Eichinger,et al.  Tissue factor-positive microparticles: Cellular origin and association with coagulation activation in patients with colorectal cancer , 2006, Thrombosis and Haemostasis.

[38]  R. Bertina,et al.  Microparticle‐associated tissue factor activity: a link between cancer and thrombosis? , 2007, Journal of thrombosis and haemostasis : JTH.

[39]  G. Agnelli,et al.  Thromboprophylaxis during chemotherapy after advanced cancer. , 2007, Thrombosis research.

[40]  A. Khorana,et al.  Approaches to risk-stratifying cancer patients for venous thromboembolism. , 2007, Thrombosis research.

[41]  N. Mackman,et al.  A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury , 2006, Thrombosis and Haemostasis.

[42]  U. Waheed,et al.  Inferior Vena Cava Filter Placement in Late-Stage Cancer , 2006, Vascular and endovascular surgery.

[43]  P. Wen,et al.  Medical management of patients with brain tumors , 2006, Journal of Neuro-Oncology.

[44]  D. Gerber,et al.  Management of venous thromboembolism in patients with primary and metastatic brain tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  H. Chew,et al.  Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  H. Chew,et al.  Incidence of venous thromboembolism and its effect on survival among patients with common cancers. , 2006, Archives of internal medicine.

[47]  P. Prandoni,et al.  Cancer and venous thromboembolism. , 1996, Seminars in thrombosis and hemostasis.

[48]  D. Cunningham,et al.  Managing Patients Treated with Bevacizumab Combination Therapy , 2005, Oncology.

[49]  A. Encke,et al.  Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients , 2005, Thrombosis and Haemostasis.

[50]  A. Turpie,et al.  Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients , 2005, Thrombosis and Haemostasis.

[51]  M. Belting,et al.  Signaling of the Tissue Factor Coagulation Pathway in Angiogenesis and Cancer , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[52]  M. Andrassy,et al.  Tissue factor as a link between wounding and tissue repair. , 2005, Diabetes.

[53]  J. Esko,et al.  The sweet and sour of cancer: glycans as novel therapeutic targets , 2005, Nature Reviews Cancer.

[54]  M. Shah,et al.  Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  N. Mackman,et al.  The synthetic pentasaccharide fondaparinux reduces coagulation, inflammation and neutrophil accumulation in kidney ischemia–reperfusion injury , 2005, Journal of thrombosis and haemostasis : JTH.

[56]  S. Shirasawa,et al.  Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. , 2005, Blood.

[57]  Erwin G. Van Meir,et al.  PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. , 2005, Cancer research.

[58]  J. S. Rao,et al.  Increased levels of plasminogen activator inhibitor-1 (PAI-1) in human brain tumors , 1993, Journal of Neuro-Oncology.

[59]  E. Arbit,et al.  Hemostatic changes in patients with brain tumors , 2005, Journal of Neuro-Oncology.

[60]  D. Schiff,et al.  Fatal pulmonary embolism despite an inferior vena cava filter in glioblastoma multiforme , 2005, Neurocritical care.

[61]  G. Lesser,et al.  The management of thromboembolic disease in patients with central nervous system malignancies , 2004, Current treatment options in oncology.

[62]  M. Cushman,et al.  Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score , 2004, Journal of thrombosis and haemostasis : JTH.

[63]  G. Rechavi,et al.  Risk of venous thromboembolism in pediatric patients with brain tumors , 2004, Pediatric blood & cancer.

[64]  P. Ascierto,et al.  Prognostic value of serum VEGF in melanoma patients: a pilot study. , 2004, Anticancer research.

[65]  J. Rak,et al.  Shedding of tissue factor (TF)‐containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells , 2004, Journal of thrombosis and haemostasis : JTH.

[66]  J. Segal,et al.  ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas , 2004, Cancer.

[67]  E. Parati,et al.  Genetic and Plasma Markers of Venous Thromboembolism in Patients with High Grade Glioma , 2004, Clinical Cancer Research.

[68]  S. Deitcher.  Cancer and Thrombosis: Mechanisms and Treatment , 2003, Journal of Thrombosis and Thrombolysis.

[69]  S. Fan,et al.  Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[70]  H. Abalı,et al.  Bevacizumab, bleeding, thrombosis, and warfarin. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  A. Vecchione,et al.  Can colorectal cancer patients with thymidylate synthase-overexpressing liver metastases have an overall survival advantage with hepatic arterial infusion alone? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  W. Aird,et al.  Regulation of tissue factor and inflammatory mediators by Egr-1 in a mouse endotoxemia model. , 2003, Blood.

[73]  L. Greenfield,et al.  Factors associated with recurrent venous thromboembolism in patients with malignant disease. , 2003, Journal of vascular surgery.

[74]  P. Black,et al.  Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. , 2002, Chest.

[75]  A. Varki,et al.  Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. , 2002, The Journal of clinical investigation.

[76]  C. Miki,et al.  Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer , 2002, American journal of hematology.

[77]  A. Kakkar,et al.  Thromboembolism in brain tumors , 2001, Current opinion in pulmonary medicine.

[78]  N. Mackman,et al.  Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. , 2001, Blood.

[79]  David R. Nadeau,et al.  Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[80]  B. Binder,et al.  Specificity, diversity, and convergence in VEGF and TNF‐α signaling events leading to tissue factor up regulation via EGR‐1 in endothelial cells , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[81]  J. Olsen,et al.  Prognosis of cancers associated with venous thromboembolism. , 2000, The New England journal of medicine.

[82]  Nigel Mackman,et al.  Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress , 2000, Nature Medicine.

[83]  W. Geerts,et al.  The risk of venous thromboembolism is increased throughout the course of malignant glioma , 2000, Cancer.

[84]  Y. Miyagi,et al.  Diverse functions of protease receptor tissue factor in inflammation and metastasis , 2000, Immunologic research.

[85]  J. Redondo,et al.  Vascular Endothelial Growth Factor Activates Nuclear Factor of Activated T Cells in Human Endothelial Cells: a Role for Tissue Factor Gene Expression , 1999, Molecular and Cellular Biology.

[86]  S. Gupta,et al.  Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. , 1998, Neurosurgery.

[87]  R. Rodas,et al.  Correlation of intraluminal thrombosis in brain tumor vessels with postoperative thrombotic complications: a preliminary report. , 1998, Journal of neurosurgery.

[88]  A. Iorio,et al.  Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. , 1998, The New England journal of medicine.

[89]  A. Brandes,et al.  Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective study , 1997 .

[90]  J. Kuratsu,et al.  Expression of tissue factor correlates with grade of malignancy in human glioma , 1996, Cancer.

[91]  M. Burt,et al.  Inferior vena cava filters in cancer patients: indications and outcome. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  J. Hirsh,et al.  Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer , 1994, The Lancet.

[93]  L. Deangelis,et al.  Therapy of venous thromboembolism in patients with brain metastases , 1994, Cancer.

[94]  J. Rand,et al.  Abnormal coagulation profile in brain tumor patients during surgery. , 1994, Neurosurgery.

[95]  R. Hellman,et al.  Venous Thromboembolism and High Grade Gliomas , 1993, Thrombosis and Haemostasis.

[96]  J. C. Torre,et al.  Astrocytes are the primary source of tissue factor in the murine central nervous system. A role for astrocytes in cerebral hemostasis. , 1993, The Journal of clinical investigation.

[97]  P. Wen,et al.  Complications of therapy for venous thromboembolic disease in patients with brain tumors , 1993, Neurology.

[98]  T. Drake,et al.  Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. , 1989, The American journal of pathology.

[99]  R. Ruff,et al.  Incidence and treatment of peripheral venous thrombosis in patients with glioma , 1983, Annals of neurology.

[100]  I. Peake.  International Society on Thrombosis and Haemostasis , 1974, Thrombosis and Haemostasis.

[101]  A. Satterfield,et al.  TREATMENT , 1924, California and western medicine.